Targeting Cancer with 3 Key Spotlight Sessions on the Latest Therapy Breakthroughs

SMi's 6th annual Cancer Vaccines event will showcase 3 key spotlight sessions on the latest advances in vaccine development and cancer therapy breakthroughs when it returns to Central London this autumn.
 
Cancer Vaccines | 27 - 27 Sept 2017
Cancer Vaccines | 27 - 27 Sept 2017
LONDON - Aug. 16, 2017 - PRLog -- This year's 6th annual Cancer Vaccines conference will feature scientists and vaccine specialists that are studying several types of cancer vaccines and how they react under different circumstances. Continued research is vital, to gain a complete overview of how well this type of treatment works and which cancers it may treat.

The following types of cancer vaccines are most commonly under investigation throughout the world and will be the key focus for this year's conference:

ANTIGEN VACCINES

Antigen vaccines are made from special proteins in cancer cells. They aim to stimulate the immune system to attack the cancer. Scientists have worked out the genetic codes of many cancer cell proteins, so they can replicate them in the lab in large quantities.

Farzin Farzaneh, Professor of Molecular Medicine, Kings College London 'Combined adjuvants for synergistic activation of cellular immunity (CASAC)' spotlight session will provide an induction of therapeutically effective cellular immunity against cancer associated antigens.

DENDRITIC CELL VACCINES

Dendritic cells help the immune system recognise and attack abnormal cells, such as cancer cells. To create the vaccine, scientists grow dendritic cells alongside cancer cells in the lab. The vaccine is then used to stimulate the immune system to attack the cancer.

Linda Powers, CEO, Northwest Biotherapeutics will explore Dendritic cells throughout her 'DCVax®: Novel personalised immune therapies for solid tumors' presentation.

DNA VACCINES

These vaccines are made with traces of DNA from cancer cells. They can be injected into the body to make the cells of the immune system more responsive to and destroying cancer cells.

Rose-Ann Padua, Research Director, INSERM 'Cell wars: the immune system fights back' session will delve into how DNA vaccines in combination with an immunomodulatory all-trans retinoic acid (ATRA) can elicit specific immune responses.

A detailed agenda and speaker line-up is available at www.cancervaccinesevent.com

Running alongside the conference will an exclusive pre-conference workshop held on Tuesday 26th September 2017.

WORKSHOP: Biomakers of Immune Response

Workshop hosts:
Rose-Ann Padua, Research Director, INSERM
Antoine Toubert
, Head, Alloimmunity, Autoimmunity, Transplantation, INSERM

Eric Tartour
, Head, Laboratory of Clinical Immunology, Hopital Europeen George Pompidou

Sharam Kordasti
, Senior Lecturer, Kings College London

Zwi Berneman
, Professor of Haematology, University of Antwerp

Cancer Vaccines 2017 is proudly sponsored by Northwest Biotherapeutics


For sponsorship packages: Contact Alia Malick +44 (0) 207 827 6168 or e-mail amalick@smi-online.co.uk.

For delegate enquiries: Contact Sean Vaghela on +44 (0) 20 7827 6744 or email saghela@smi-online.co.uk

For media enquiries, contact Kyra Williams on +44 (0) 20 7827 6012 or email kwilliams@smi-online.co.uk

6th annual Cancer Vaccines

27th – 28th September 2017

London, UK

www.cancervaccinesevent.com
Contact e-mail: kwilliams@smi-online.co.uk
Contact tel: +44 (0) 207 827 6012
#smicancervac

End
Source:SMi Group
Email:***@smi-online.co.uk Email Verified
Tags:Cancer, Vaccines, Therapies, Novel, T-cell, Antigen, Immune, Personalising, Biomarkers, Tumors
Industry:Health, Marketing, Medical, Science
Location:London City - London, Greater - England
Subject:Events
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share